激酶-话题@MedSci

#激酶#

224篇内容 | 2174人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1496108, encodeId=b55a149610829, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, objectType=article, longId=211606, objectId=ff0121160699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0121160699, replyNumber=0, likeNumber=23, createdTime=2021-05-22, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0121160699, moduleTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0121160699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496107, encodeId=8007149610e5a, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, objectType=article, longId=211491, objectId=32e221149157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e221149157, replyNumber=0, likeNumber=35, createdTime=2021-05-20, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e221149157, moduleTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32e221149157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496106, encodeId=0178149610621, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Nat Commun：类泛素化控制己糖激酶2与线粒体的结合并预防前列腺癌肿瘤发生, objectType=article, longId=209753, objectId=aa78209e53a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa78209e53a7, replyNumber=0, likeNumber=0, createdTime=2021-04-11, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa78209e53a7, moduleTitle=Nat Commun：类泛素化控制己糖激酶2与线粒体的结合并预防前列腺癌肿瘤发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa78209e53a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496105, encodeId=c375149610542, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, objectType=article, longId=209220, objectId=b2172092201a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2172092201a, replyNumber=0, likeNumber=35, createdTime=2021-04-01, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2172092201a, moduleTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2172092201a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496104, encodeId=dfdf1496104de, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Lancet：舒尼替尼与三种MET激酶抑制剂用于转移性乳头状肾细胞癌的疗效对比, objectType=article, longId=207346, objectId=f9b820e346bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9b820e346bb, replyNumber=0, likeNumber=40, createdTime=2021-02-21, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9b820e346bb, moduleTitle=Lancet：舒尼替尼与三种MET激酶抑制剂用于转移性乳头状肾细胞癌的疗效对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9b820e346bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496103, encodeId=fb2514961036e, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Br J Cancer：三种靶向HER2的酪氨酸激酶抑制剂的比较分析, objectType=article, longId=206381, objectId=297020638150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297020638150, replyNumber=0, likeNumber=37, createdTime=2021-01-30, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297020638150, moduleTitle=Br J Cancer：三种靶向HER2的酪氨酸激酶抑制剂的比较分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297020638150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496102, encodeId=649f149610221, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=J Gastroenterol：多靶点小分子酪氨酸激酶抑制剂卡博替尼可有效治疗晚期肝癌, objectType=article, longId=205516, objectId=f6672055161a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6672055161a, replyNumber=0, likeNumber=35, createdTime=2021-01-10, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6672055161a, moduleTitle=J Gastroenterol：多靶点小分子酪氨酸激酶抑制剂卡博替尼可有效治疗晚期肝癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6672055161a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496101, encodeId=5301149610171, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Blood：Bruton酪氨酸激酶抑制剂会不会影响疫苗接种的效果？, objectType=article, longId=204130, objectId=4c7620413018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c7620413018, replyNumber=0, likeNumber=0, createdTime=2020-12-06, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c7620413018, moduleTitle=Blood：Bruton酪氨酸激酶抑制剂会不会影响疫苗接种的效果？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c7620413018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496100, encodeId=3835149610026, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Cell Death Differ：RIP1激酶通过介导巨噬细胞死亡和炎症反应促进非酒精性脂肪肝炎的发生, objectType=article, longId=203773, objectId=d5bc203e7384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5bc203e7384, replyNumber=0, likeNumber=0, createdTime=2020-11-27, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5bc203e7384, moduleTitle=Cell Death Differ：RIP1激酶通过介导巨噬细胞死亡和炎症反应促进非酒精性脂肪肝炎的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5bc203e7384)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496099, encodeId=f49614960996a, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=多激酶抑制剂ON 123300治疗复发/难治性晚期癌症：即将开展I期临床研究, objectType=article, longId=203706, objectId=f94a203e06d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94a203e06d6, replyNumber=0, likeNumber=44, createdTime=2020-11-26, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94a203e06d6, moduleTitle=多激酶抑制剂ON 123300治疗复发/难治性晚期癌症：即将开展I期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f94a203e06d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496098, encodeId=c82c149609820, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=JAMA Oncology：慢性髓细胞白血病患者停用酪氨酸激酶抑制剂后的预后评估, objectType=article, longId=203471, objectId=188b2034e1e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=188b2034e1e6, replyNumber=0, likeNumber=17, createdTime=2020-11-18, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=188b2034e1e6, moduleTitle=JAMA Oncology：慢性髓细胞白血病患者停用酪氨酸激酶抑制剂后的预后评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=188b2034e1e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496097, encodeId=f217149609e71, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Circulation：T细胞内源性生成的硫化氢通过硫化肝激酶B1缓解高血压, objectType=article, longId=202996, objectId=a11a20299673, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a11a20299673, replyNumber=0, likeNumber=39, createdTime=2020-11-08, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a11a20299673, moduleTitle=Circulation：T细胞内源性生成的硫化氢通过硫化肝激酶B1缓解高血压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a11a20299673)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496096, encodeId=e66414960965f, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Acta Neuropathologica: MAP激酶p38γ降低tau介导的晚期记忆缺陷, objectType=article, longId=201974, objectId=a7412019e4df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7412019e4df, replyNumber=0, likeNumber=22, createdTime=2020-10-12, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7412019e4df, moduleTitle=Acta Neuropathologica: MAP激酶p38γ降低tau介导的晚期记忆缺陷, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7412019e4df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496095, encodeId=017c149609533, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Cancer cell：原来T细胞也会“衰老”，中国科学家揭示调节T细胞衰竭的关键激酶, objectType=article, longId=200574, objectId=c7a12005e413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a12005e413, replyNumber=0, likeNumber=33, createdTime=2020-09-13, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a12005e413, moduleTitle=Cancer cell：原来T细胞也会“衰老”，中国科学家揭示调节T细胞衰竭的关键激酶, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7a12005e413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496094, encodeId=60be149609438, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=NEJM：Janus激酶抑制剂在小儿Aicardi-Goutieres综合征中的作用, objectType=article, longId=200383, objectId=b6972003833b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6972003833b, replyNumber=0, likeNumber=22, createdTime=2020-09-09, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6972003833b, moduleTitle=NEJM：Janus激酶抑制剂在小儿Aicardi-Goutieres综合征中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6972003833b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496093, encodeId=790b14960936b, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Nat Commun：靶向线粒体激酶可治疗扩张型心肌病, objectType=article, longId=200308, objectId=6ffd20030824, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ffd20030824, replyNumber=0, likeNumber=37, createdTime=2020-09-07, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ffd20030824, moduleTitle=Nat Commun：靶向线粒体激酶可治疗扩张型心肌病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ffd20030824)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496092, encodeId=f7401496092ad, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Immunity：从复杂的自体炎症性疾病揭示JAK1激酶的基本功能, objectType=article, longId=199641, objectId=5942199641a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5942199641a8, replyNumber=0, likeNumber=38, createdTime=2020-08-20, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5942199641a8, moduleTitle=Immunity：从复杂的自体炎症性疾病揭示JAK1激酶的基本功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5942199641a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496091, encodeId=1b8f149609154, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Clin Cancer Res：WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌, objectType=article, longId=199405, objectId=b6411994055d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6411994055d, replyNumber=0, likeNumber=43, createdTime=2020-08-15, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6411994055d, moduleTitle=Clin Cancer Res：WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6411994055d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496090, encodeId=7f07149609046, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, objectType=article, longId=199330, objectId=176519933069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=176519933069, replyNumber=0, likeNumber=25, createdTime=2020-08-14, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=176519933069, moduleTitle=鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=176519933069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1496089, encodeId=75fb149608981, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, objectTitle=Science：Bruton酪氨酸激酶治疗重症COVID-19患者的疗效, objectType=article, longId=195519, objectId=c8f51955192f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8f51955192f, replyNumber=0, likeNumber=28, createdTime=2020-06-10, rootId=0, userName=redcrab, userId=73449239400, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8f51955192f, moduleTitle=Science：Bruton酪氨酸激酶治疗重症COVID-19患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8f51955192f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激酶

2020-05-29

redcrab (审核中...)

前往app查看评论内容

#激酶#

Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估

2021-05-22

redcrab (审核中...)

前往app查看评论内容

#激酶#

Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性

2021-05-20

redcrab (审核中...)

前往app查看评论内容

#激酶#

Nat Commun：类泛素化控制己糖激酶2与线粒体的结合并预防前列腺癌肿瘤发生

2021-04-11

redcrab (审核中...)

前往app查看评论内容

#激酶#

Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！

2021-04-01

智慧医人 (审核中...)

前往app查看评论内容

#激酶#

Lancet：舒尼替尼与三种MET激酶抑制剂用于转移性乳头状肾细胞癌的疗效对比

2021-02-21

redcrab (审核中...)

前往app查看评论内容

#激酶#

Br J Cancer：三种靶向HER2的酪氨酸激酶抑制剂的比较分析

2021-01-30

redcrab (审核中...)

前往app查看评论内容

#激酶#

J Gastroenterol：多靶点小分子酪氨酸激酶抑制剂卡博替尼可有效治疗晚期肝癌

2021-01-10

redcrab (审核中...)

前往app查看评论内容

#激酶#

Blood：Bruton酪氨酸激酶抑制剂会不会影响疫苗接种的效果？

2020-12-06

redcrab (审核中...)

前往app查看评论内容

#激酶#

Cell Death Differ：RIP1激酶通过介导巨噬细胞死亡和炎症反应促进非酒精性脂肪肝炎的发生

2020-11-27

redcrab (审核中...)

前往app查看评论内容

#激酶#

多激酶抑制剂ON 123300治疗复发/难治性晚期癌症：即将开展I期临床研究

2020-11-26

redcrab (审核中...)

前往app查看评论内容

#激酶#

JAMA Oncology：慢性髓细胞白血病患者停用酪氨酸激酶抑制剂后的预后评估

2020-11-18

redcrab (审核中...)

前往app查看评论内容

#激酶#

Circulation：T细胞内源性生成的硫化氢通过硫化肝激酶B1缓解高血压

2020-11-08

redcrab (审核中...)

前往app查看评论内容

#激酶#

Acta Neuropathologica: MAP激酶p38γ降低tau介导的晚期记忆缺陷

2020-10-12

redcrab (审核中...)

前往app查看评论内容

#激酶#

Cancer cell：原来T细胞也会“衰老”，中国科学家揭示调节T细胞衰竭的关键激酶

2020-09-13

redcrab (审核中...)

前往app查看评论内容

#激酶#

NEJM：Janus激酶抑制剂在小儿Aicardi-Goutieres综合征中的作用

2020-09-09

hb2008ye (审核中...)

前往app查看评论内容

#激酶#

Nat Commun：靶向线粒体激酶可治疗扩张型心肌病

2020-09-07

redcrab (审核中...)

前往app查看评论内容

#激酶#

Immunity：从复杂的自体炎症性疾病揭示JAK1激酶的基本功能

2020-08-20

redcrab (审核中...)

前往app查看评论内容

#激酶#

Clin Cancer Res：WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌

2020-08-15

redcrab (审核中...)

前往app查看评论内容

#激酶#

鞘氨醇激酶2抑制剂Opaganib治疗COVID-19：II/III期研究已在墨西哥获得批准

2020-08-14

redcrab (审核中...)

前往app查看评论内容

#激酶#

Science：Bruton酪氨酸激酶治疗重症COVID-19患者的疗效

2020-06-10

科室
- - 订阅+
  - 更多科室
工具
服务